Quick Answer
enGene Therapeutics Inc. reported Earnings Per Share Diluted of $2.29 per share for the year ending 2025.
- enGene Therapeutics Inc. showed an increase of +56.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Earnings Per Share Diluted has declined by 94.8%.
- Historical annual values: Fiscal year 2025: $2.29 per share | Fiscal year 2024: $1.46 per share | Fiscal year 2023: $151.22 per share | Fiscal year 2022: $44.30 per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: